Results For Bayer's Xarelto In Japanese Phase III Trial In Line With Expectations
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Bayer AG's anticoagulant Xarelto (rivaroxaban) met its primary endpoint of clinically relevant bleeding - major and non-major bleeding - in a Japanese Phase III trial, in line with the drug's performance in a 14,000+ global Phase III study, easing the path for approval in Japan